Upcoming Events
  1. ***UPDATED*** ALTG Members’ Meeting, Sydney NSW

    November 24
  2. ***UPDATED*** 2017 ALTG Lung Cancer Symposium, Sydney NSW

    November 24 @ 9:00 am - November 25 @ 5:00 pm UTC+10

ALTG 11/002 Temozolomide and PARPI as 2LC for SCLC

Phase I/II study of temozolomide and PARP (Poly ADP ribose polymerase) inhibitor as a second line chemotherapy for SCLC. This study concept is on hold and will be reviewed once the results of an ongoing Phase 1 study at UCLA exploring the combination are available.

Any further enquiries regarding this trial should be directed to the CTC Clinical Lead A/Prof Martin Stockler, atmartin.stockler@sydney.edu.au